Benzimidazole compounds

Abstract

This invention relates generally to benzimidazole-based modulators of Liver X receptors (LXRs) and related methods (Formula I). wherein R2 is C6-C10 aryl or heteroaryl including 5-10 atoms, each of which is: (i) substituted with 1 R7, and (ii) optionally substituted with from 1-5 Re; and R1, R3, R4, R5, R6, R7, and Re are defined herein.

Description

Cross References to Related Applications This application claims the benefit of US Provisional Application No. 61 / 016,070, filed December 21, 2007, which is hereby incorporated by reference in its entirety. technical field The present invention relates generally to benzimidazole-based modulators of liver X receptors (LXRs) and related methods. Background technique Arteriosclerosis is one of the leading causes of death in developed countries. Some independent risk factors associated with arteriosclerosis include the presence of relatively high serum LDL cholesterol levels and relatively low serum HDL cholesterol levels in affected patients. Thus, some anti-atherosclerotic treatment regimens involve the administration of agents such as statins to reduce elevated serum LDL cholesterol levels. Agents that increase HDL cholesterol levels in a patient may also be used in anti-atherosclerotic regimens. It is believed that HDL cholesterol plays a major role in the process of ...

AI Technical Summary

Problems solved by technology

In addition to the lipid and triglyceride effects described above, it is also believed that activation of LXRs results in inhibition of inflammatory and pro-inflammatory gene expression

Images